Waters Completes Merger with BD Biosciences Division
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy WAT?
Source: PRnewswire
- Merger Completion: Waters Corporation has successfully completed its merger with Becton, Dickinson and Company's Biosciences and Diagnostic Solutions businesses, forming a global leader in life sciences and diagnostics, which is expected to drive expansion in high-growth markets.
- New Board Member: Dr. Claire M. Fraser has been appointed to the Waters Board, increasing its size to 11 members; with three decades of experience in genomics and molecular diagnostics, her expertise will significantly support the company's future growth.
- Market Positioning: Post-merger, Waters has established four new divisions focused on high-volume testing and expansion into adjacent markets, aiming to leverage leading scientific teams to advance the development of large and small molecule therapeutics.
- Equity Structure: Following the merger, Waters shareholders own 60.8% of the combined company while BD shareholders hold 39.2%, achieved through a Reverse Morris Trust transaction that secures Waters' dominant position in the new entity.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy WAT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on WAT
Wall Street analysts forecast WAT stock price to rise
13 Analyst Rating
8 Buy
5 Hold
0 Sell
Moderate Buy
Current: 319.830
Low
350.00
Averages
414.08
High
480.00
Current: 319.830
Low
350.00
Averages
414.08
High
480.00
About WAT
Waters Corporation offers analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences. The Company's segments include Waters and TA. The Company primarily designs, manufactures, sells and services high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans. The Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its TA Instruments (TA) product line. The Company is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments. It operates directly in over 35 countries and has products available in more than 100 countries.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Sales Performance Beat: Becton Dickinson reported sales of $5.25 billion, slightly exceeding the consensus of $5.15 billion, indicating stable performance in a challenging economic environment despite ongoing headwinds.
- Earnings Guidance Cut: The company lowered its fiscal 2026 adjusted earnings guidance from $14.75-$15.05 per share to $12.35-$12.65, below the consensus of $14.72, reflecting pressures and uncertainties in future business operations.
- Analyst Rating Changes: RBC Capital Markets reduced its price target for Becton Dickinson from $210 to $172, citing FY26 as a transition year with an expected organic revenue growth of 2.5%, which may impact investor confidence moving forward.
- Market Reaction: Following the announcement, Becton Dickinson's shares fell by 17.44% to $171.23, indicating investor concerns regarding the company's growth potential, especially in light of multiple business headwinds.
See More
- Market Sentiment: Bulls have regained control of the market following previous concerns over artificial intelligence, leading to a positive outlook for risky assets, particularly in the tech sector.
- Ongoing Rally: The rally in real assets continues as investors anticipate a series of important economic data releases in the coming days.
See More
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
- U.S. Stock Market Performance: U.S. stock indexes experienced gains on Monday, with the overall market rising by 0.90%.
- Specific Index Movements: The S&P 500 increased by 0.47%, while the Dow Jones Industrial Average saw a slight rise of 0.04%.
See More
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
- Software Stock Rebound: Following last week's severe selloff, the iShares Expanded Tech-Software Sector ETF (NYSE:IGV) jumped over 3% on Monday, marking its strongest daily gain since late April 2025, indicating renewed investor interest in software stocks and a potential recovery in market confidence.
- Nasdaq Outperformance: The Nasdaq 100 climbed 1%, significantly outperforming broader Wall Street, while the S&P 500 added 0.7%, suggesting that the strong rebound in tech stocks is driving overall market gains and may attract more capital inflows.
- Individual Stock Surge: AppLovin Corp. (NASDAQ:APP) surged more than 14% after logging four consecutive weekly declines, reflecting optimistic market sentiment regarding its future growth potential, which could draw more investor attention to the company.
- Commodity Market Recovery: Oil prices rose over 2% to $64.6 a barrel, while gold rebounded 2.5% to $5,090 an ounce, and silver soared over 6% to $82 an ounce, indicating an improvement in market risk appetite that may positively impact related industries.
See More








